Antiplatelet drug is a pharmaceutical drug that reduces blood aggregation and inhibits thrombus formation. As, these drugs interfere the process of blood clot formation that accelerates the production of thrombin which stabilises the conversion of fibrogen to fibrin and dissolves the blood clots. Antiplatelet drugs are majorly used in the treatment and prevention of arterial thrombosis, which results into consequences of heart attack and relative cardiovascular disorders. Antiplatelet drugs are also called as Antithrombotic drugs.

Major indications treated with antiplatelet/antithrombotic drugs are all the cardiovascular diseases, acute ischaemic events, and atrial fibrillation. These indications are majorly caused due to damage of vessels, pregnancy, obesity, and genetics. Moreover, increasing smoking trend globally has also increased the prevalence these indications and has promoted the use of these drugs. According to CDC, smoking is one of the leading cause of death in the U.S.; every 1 out of 5 deaths in the U.S. are caused due to smoking.

Increasing production of generic antiplatelet drugs and significant increase for research and development globally to boost the antiplatelet market.

The global antiplatelet market is primarily driven by the factors like increasing use of antiplatelet/antithrombotic drugs for treating various disorders, rising ageing population, increasing thrombotic events globally, and increase in research and development for developing new drugs. Moreover, rising number incidences cardiovascular disorders of would also spur the market of these drugs. According to American Heart Association, heart stroke is no.1 leading cause of death in the U.S. i.e. someone in the U.S. have stroke every 40 seconds.   In addition, the continuous increase in the investment for developing new drugs by the manufacturers by rising investment on research, and formation of executive products for the potential market would influence a positive growth for entire industry.

However, side effects like gastrointestinal disturbance and bleeding caused by all types of antiplatelet/antithrombotic drugs will hinder the market growth during the forecast period.

Global Antiplatelet Market Taxonomy

The global antiplatelet drug market is segmented on the basis of drugs, end users and geography.

• By Drug type
  • Anticoagulant Drug
  • Antiplatelet Drugs
  • Thrombolytic Drugs
• By End Users
  • Hospitals
  • Emergency Service Centres
  • Ambulatory Surgery Centres
  • Others

Geographically, the global antiplatelet market is categorized into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Rising elderly population to lead the global antiplatelet market in North America.

On the basis of geography, North America is expected to dominate the global antiplatelet drugs market over forecast period. The primary factors influencing growth of antiplatelet drug market in this region are increasing elderly population in North America, and high availability of patients suffering from cardiovascular diseases will positively influence the market of North Americas during the forecast period. While, Europe holds the second largest share for the market owning to the increasing geriatric population. The geriatric population in Europe is mainly attributed to the increased life expectancy, and improved medical infrastructure for treating various diseases.

However, Asia Pacific is expected to dominate the market in the forecast period. Increasing awareness for the use of antiplatelet drugs in treating various indication, and increasing geriatric population.

Key players in the global antiplatelet market are:

• Bayer Healthcare AG.
• AstraZenca
• Portola Pharmaceuticals, Inc.
• Bristol-Myers Squibb Company
• Boehringer Inghelheim Pharmaceutical, Inc.
• Altimed Pharma Inc.
• Altra laboratoriesLtd.
• Hoffmanm La Roche
• Nanjing Pharmaceutical Factory
• Microbix Biosystems Inc.
• The Medicine Co.
• Emisphere Technologies
• Eli-Lily Co.
• Biovascular Inc.
• Daiichi Sankyo Co.
• Pfizer Inc.